The treatment of patients with refractory/relapsed B cell non-Hodgkin lymphoma (NHL) is evolving because of the availability of novel drugs. Allogeneic stem cell transplantation (alloSCT) can be curative, but its morbidity and mortality remain a matter of concern. We conducted a multicenter prospective phase II trial to evaluate the benefit of including only 1 dose of rituximab in the conditioning regimen before alloSCT. The primary endpoint was progression-free survival. The study enrolled 121 patients with relapsed/refractory B cell lymphomas. The conditioning regimen consisted of thiotepa, cyclophosphamide, fludarabine, and rituximab (500 mg/m2). Rabbit antithymocyte globulin was administered only in case of unrelated donors. Sixty-seven (55%) and 54 (45%) patients received grafts from related and unrelated donors, respectively. The crude cumulative incidence (CCI) of nonrelapse mortality (NRM) was 21% at 3 years. The CCIs of chronic graft-verus-host disease (GVHD) at 3 years were 54% and 31% in recipients of matched sibling and unrelated grafts, respectively. At a median follow-up of 41 months, the estimated 3-year progression-free and overall survival were 50% and 61%, respectively. Long-term outcome was also evaluated with the composite endpoint of GVHD-free and relapse-free survival (GRFS). This is the first work evaluating the GRFS in a prospective trial of lymphoma patients: the 1-year and 3-year GRFS were 40% and 34%, respectively. AlloSCT can cure a fraction of patients with rather low NRM and an encouraging PFS and GRFS.
Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen / Dodero, Anna; Patriarca, Francesca; Milone, Giuseppe; Sarina, Barbara; Miceli, Rosalba; Iori, Anna; Barretta, Francesco; Terruzzi, Elisabetta; Mussetti, Alberto; Pini, Massimo; Bosi, Alberto; Dominietto, Alida; Cascavilla, Nicola; Onida, Francesco; Narni, Franco; Farina, Lucia; Rambaldi, Alessandro; Corradini, Paolo. - In: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. - ISSN 1083-8791. - 23:7(2017), pp. 1102-1109.
Data di pubblicazione: | 2017 |
Data di prima pubblicazione: | 5-apr-2017 |
Titolo: | Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen |
Autore/i: | Dodero, Anna; Patriarca, Francesca; Milone, Giuseppe; Sarina, Barbara; Miceli, Rosalba; Iori, Anna; Barretta, Francesco; Terruzzi, Elisabetta; Mussetti, Alberto; Pini, Massimo; Bosi, Alberto; Dominietto, Alida; Cascavilla, Nicola; Onida, Francesco; Narni, Franco; Farina, Lucia; Rambaldi, Alessandro; Corradini, Paolo |
Autore/i UNIMORE: | |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1016/j.bbmt.2017.03.031 |
Rivista: | |
Volume: | 23 |
Fascicolo: | 7 |
Pagina iniziale: | 1102 |
Pagina finale: | 1109 |
Codice identificativo ISI: | WOS:000404065400011 |
Codice identificativo Scopus: | 2-s2.0-85019352735 |
Codice identificativo Pubmed: | 28390983 |
Citazione: | Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen / Dodero, Anna; Patriarca, Francesca; Milone, Giuseppe; Sarina, Barbara; Miceli, Rosalba; Iori, Anna; Barretta, Francesco; Terruzzi, Elisabetta; Mussetti, Alberto; Pini, Massimo; Bosi, Alberto; Dominietto, Alida; Cascavilla, Nicola; Onida, Francesco; Narni, Franco; Farina, Lucia; Rambaldi, Alessandro; Corradini, Paolo. - In: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. - ISSN 1083-8791. - 23:7(2017), pp. 1102-1109. |
Tipologia | Articolo su rivista |
File in questo prodotto:
File | Descrizione | Tipologia | |
---|---|---|---|
Dodero et al_Biol Blood Marrow Transplan 2017.pdf | Versione dell'editore (versione pubblicata) | Open Access Visualizza/Apri |

I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris